NORTHBROOK, Ill.—Nanotechnology life sciences company Nanosphere Inc. recently announced the hiring of Gregory Shipp, M.D., as vice president of medical affairs to spearhead the company's commercialization efforts of its Verigene genomic and proteomic diagnostic tool.

 

According to the company, the Verigene system can simultaneously provide ultra-sensitive genomic and proteomic testing on a single instrument on a scale five to six times more sensitive than current standards.

 

Positioned primarily as a diagnostic tool, Verigene has the potential to aid treatment of recurrent cancer or neurodegenerative diseases. "The potential for the greatest payback is where there is recurrent or very slow onset disease such as cancer," says William Moffitt, president and CEO.

 

Shipp's role with the company is to consult with physicians to "be a voice in the community and to understand their needs," he says.